Dr. Edward Paul answers the question: 'How Does Chronic Pain Differ From Acute?' — -- Question: What Is Chronic Pain And How Does It Differ From Acute Pain? Answer: Chronic pain and acute pain ...

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

Pain has the potential to affect various aspects of a person’s life, from disrupting one’s daily routine to negatively impacting emotional well-being. It’s also one of the most common reasons that ...

SHANGHAI--(BUSINESS WIRE)--Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: ...

With the world in an opioid crisis, the development of non-opioid analgesics has become more urgent. A series of Phase 3 clinical trials into a novel oral, non-opioid painkiller has found that it’s ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC News reported. The drug, Journavx, or suzetrigine, was approved to treat ...

Approximately 7.6 million individuals in the United States suffer from opioid use disorder (OUD). Three evidence-based medications—methadone, buprenorphine, and naltrexone—are recommended for use by ...

Please provide your email address to receive an email when new articles are posted on . Journavx became the first drug in a new class of pain management medications to be FDA approved. The treatment ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...